A MULTINATIONAL, INVESTIGATOR-INITIATED, PARALLEL GROUP, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3B SUPERIORITY TRIAL ASSESSING THE EFFECT OF DUPILUMAB ON INDUCING CLINICAL REMISSION OUTCOMES IN AT-RISK TYPE-2 INFLAMMATORY ASTHMA (HOTHOT)

Registry ID

2024ESR0000238

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

UNIVERSITÉ DE SHERBROOKE

Start date

2026-04-16

Last update

2025-11-25

Conditions

• ASTHMA

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A STUDY OF ARO-RAGE INHALATION SOLUTION TO ASSESS EFFICACY ON SMALL AIRWAY DYSFUNCTION IN ALLERGEN-INDUCED MILD ASTHMA
• A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 52-WEEK STUDY, TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR THE TREATMENT OF ADULT PARTICIPANTS WITH UNCONTROLLED MODERATE TO SEVERE ASTHMA
• PAXT: PULMONARY IMAGING OF MILD ASTHMA USING 129-XENON MRI AND TC-99-LABELED-CARBON-IMAGING (TC99CIMAGING)
• REVERSE LUNG AIRWAY AND VASCULAR REMODELING IN ASTHMA REMISSION (RENORM)
• TEZEPELUMAB IN THE TREATMENT OF EMERGENCY ROOM ASTHMA IN ADULTS (TERAA): A PHASE 4 DOUBLE-BLINDED, PARALLEL-GROUP RANDOMIZED CONTROL TRIAL WITH AN OPEN LABEL EXTENSION
• MAGNESIUM TRIAL IN ACUTE ASTHMA IN EMERGENCY DEPARTMENT (MAGICIAN)

View on source registry